Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04390984 | Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients | unknown | Phase 1 | 22 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04448379 | Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 | 48 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 28, 2020 | clinicaltrials |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 99 | MedImmune LLCINDUSTRY | 7 | Dec 23, 2020 | clinicaltrials |
| NCT00434174 | Safety of Everolimus and Pemetrexed in Lung Cancer Patients | completed | Phase 1 | 48 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 21, 2020 | clinicaltrials |
| NCT00456833 | Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy | completed | Phase 1 | 248 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 21, 2020 | clinicaltrials |
| NCT00535951 | Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01772797 | Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer | completed | Phase 1 | 22 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02292550 | Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. | completed | Phase 1 | 27 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 17, 2020 | clinicaltrials |
| NCT03246854 | A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | terminated | Phase 1 | 6 | National Health Research Institutes, TaiwanOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04667975 | The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy(CKD-702) | unknown | Phase 1 | 74 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Regeneron PharmaceuticalsINDUSTRY | 2 | Dec 10, 2020 | clinicaltrials |
| NCT00674102 | An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01999985 | Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma(N3) | withdrawn | Phase 1 / Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT01958372 | Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 11 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT00821951 | Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer | completed | Phase 1 | 17 | Yale UniversityOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04006301 | First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation | completed | Phase 1 | 10 | Janssen Research & Development, LLCINDUSTRY | 2 | Nov 6, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00832117 | Phase I Combination Ixabepilone + Cisplatin | completed | Phase 1 | 30 | R-PharmINDUSTRY | 2 | Oct 28, 2020 | clinicaltrials |
| NCT01188707 | A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 5 | Herlev HospitalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02879760 | Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 16 | Turnstone Biologics, Corp.INDUSTRY | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02451930 | A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC | completed | Phase 1 | 71 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 5, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT03502850 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 507 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02079636 | A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | completed | Phase 1 | 142 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 11, 2020 | clinicaltrials |
| NCT01189968 | A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 | 50 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 | clinicaltrials |
| NCT01784640 | Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer | completed | Phase 1 | 13 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT03450330 | Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer(JACKPOT1) | completed | Phase 1 / Phase 2 | 10 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 24, 2020 | clinicaltrials |
| NCT04510415 | Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI | terminated | Phase 1 | 2 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01526928 | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | terminated | Phase 1 / Phase 2 | 612 | Clovis Oncology, Inc.INDUSTRY | 4 | Aug 4, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04487093 | Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer | unknown | Phase 1 | 20 | First Hospital of Shijiazhuang CityOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02451865 | Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02411591 | A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 66 | Eli Lilly and CompanyINDUSTRY | 3 | Jul 9, 2020 | clinicaltrials |
| NCT03415126 | A Study of ASN007 in Patients With Advanced Solid Tumors | completed | Phase 1 | 49 | Asana BioSciencesINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT04273815 | A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | unknown | Phase 1 / Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT01199055 | CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 16 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03987867 | Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04193098 | Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC | unknown | Phase 1 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | terminated | Phase 1 | 79 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT03181308 | Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC | completed | Phase 1 | 11 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jun 24, 2020 | clinicaltrials |
| NCT03326752 | Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | completed | Phase 1 | 26 | Dynavax Technologies CorporationINDUSTRY | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04397926 | Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer | unknown | Phase 1 | 20 | Sun Yat-sen UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT01803282 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | completed | Phase 1 | 236 | Gilead SciencesINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jan 11, 2021source: clinicaltrials